EL7.AI
Stocks•9 July 2026•
1 min read

Analysts Boost Price Targets for West Pharmaceutical and Charles River Laboratories

Key Facts

1Analysts raised the average price target for West Pharmaceutical Services to $370.23, implying a 5% potential upside.
2The price target for Charles River Laboratories was raised to $226.79, with a consensus 'Buy' rating from 20 analysts.

Amid a period of steady performance in the healthcare sector, analysts have incrementally raised the 12-month price targets for West Pharmaceutical Services and Charles River Laboratories. According to reports, the average price target for West Pharmaceutical was adjusted to $370.23, implying a potential upside of 5%. Similarly, the target for Charles River Laboratories was lifted to $226.79, supported by a strong consensus 'Buy' rating from a group of 20 analysts.

This optimism is rooted in the resilience of the life sciences industry; West Pharmaceutical has recently demonstrated stable growth in pharmaceutical packaging demand, while Charles River benefits from a recovery in biotech R&D budgets. Compared to industry peers, experts suggest these revisions reflect growing confidence in operating margins as global supply chains stabilize, according to market data and recent sectoral analysis.

Looking ahead, investors are closely monitoring U.S. monetary policy shifts that could impact valuations for growth-oriented healthcare stocks. ISM Services PMI scheduled for July, which may provide insights into input costs and broader spending trends in non-manufacturing sectors.